Pirtobrutinib
Författaruppgift saknas
Tidskrift saknas · review PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för pirtobrutinib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
28 träffarPirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Al-Sawaf O, Jen MH, Hess LM, Zhang J, Goebel B, Pagel JM, Abhyankar S, Davids MS, Eyre TA.
Haematologica · clinical trial, phase ii; comparative study; research-article; clinical trial, phase i; journal article · DOI 10.3324/haematol.2023.284150Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Woolston DW, Lee ND, Shadman M, Latorre-Esteves E, Tee XR, Fredrickson J, Kohrn BF, Ujjani C, Eckel A, Till B, Fang M, Radich J, Bozic I, Risques RA, Yeung CCS.
Haematologica · research support, non-u.s. gov't; journal article · DOI 10.3324/haematol.2023.283372Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies.
Schultze MD, Reeves DJ.
Ann Pharmacother · journal article · DOI 10.1177/10600280231223737FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
Telaraja D, Kasamon YL, Collazo JS, Leong R, Wang K, Li P, Dahmane E, Yang Y, Earp J, Grimstein M, Rodriguez LR, Theoret MR, Gormley NJ.
Clin Cancer Res · research-article; journal article · DOI 10.1158/1078-0432.ccr-23-1272Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
De SK.
Curr Med Chem · review; journal article · DOI 10.2174/0109298673251030231004052822Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Davis DD, Ohana Z, Pham HM.
J Oncol Pharm Pract · review; journal article · DOI 10.1177/10781552231216886[Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma].
Fileni C, Sarkozy C.
Bull Cancer · letter · DOI 10.1016/j.bulcan.2023.07.002Recent approval of pirtobrutinib for mantle cell lymphoma.
Cohen JB.
Clin Adv Hematol Oncol · interviewNon-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia.
Montoya S, Thompson MC.
Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers15143648Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, Hanson LM, Brown NE, Gong X, Stephens J, Wu W, Lippincott I, Ku KS, Walgren RA, Abada PB, Ballard JA, Allerston CK, Brandhuber BJ.
Blood · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1182/blood.2022018674Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W.
N Engl J Med · clinical trial, phase ii; clinical trial, phase i; journal article · DOI 10.1056/nejmoa2300696Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
Thompson PA, Tam CS.
Blood · review-article; journal article · DOI 10.1182/blood.2023020240Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN.
J Clin Oncol · research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1200/jco.23.00562The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.
Eyre TA, Riches JC.
Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers15092596Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR.
Blood Adv · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/bloodadvances.2022008447Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma.
Liu Y, Yan F, Jiang VC, Li Y, Che Y, McIntosh J, Jordan A, Hou I, Nie L, Jin J, Wang W, Lee HH, Yao Y, Wang M.
Haematologica · letter; research support, non-u.s. gov't · DOI 10.3324/haematol.2022.282031Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib.
Bye AP, Kriek N, Sage T, Rawlings SJ, Prodger C, Kesavan M, Lees C, Booth S, Cowen LG, Shefferd K, Desborough MJ, Gibbins JM, Eyre TA.
Haematologica · letter; research support, non-u.s. gov't · DOI 10.3324/haematol.2022.281402Pirtobrutinib.
Författaruppgift saknas
Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxad051Pirtobrutinib: First Approval.
Keam SJ.
Drugs · review; journal article · DOI 10.1007/s40265-023-01860-1Pirtobrutinib (Jaypirca): A fourth Bruton's tyrosine kinase inhibitor for mantle cell lymphoma.
Författaruppgift saknas
Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1670fBRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML.
Future Oncol · clinical trial protocol; journal article · DOI 10.2217/fon-2022-0976Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, Lewis KL, Handunnetti SM, Tang CPS, Roberts A, Seymour JF, Tam CS.
Blood Adv · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1182/bloodadvances.2022008325The potential of pirtobrutinib in multiple B-cell malignancies.
Jensen JL, Mato AR, Pena C, Roeker LE, Coombs CC.
Ther Adv Hematol · review-article; review; journal article · DOI 10.1177/20406207221101697Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V.
Blood Cancer J · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41408-022-00675-9The emerging role of pirtobrutinib in chronic lymphocytic leukemia.
Lamanna N.
Clin Adv Hematol Oncol · interviewMechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O.
N Engl J Med · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa2114110Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M.
Lancet · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/s0140-6736(21)00224-5